Real-World Outcomes of Brexu-cel in R/R B-Cell ALL

Evandro D. Bezerra, MD, the Ohio State Comprehensive Cancer Center – James Cancer Hospital & Solove Research Institute, provides real-world data from the CIBMTR Registry, examining the effectiveness of brexucabtagene autoleucel (Tecartus; brexu-cel) for the treatment of patients with relapsed/refractory B-cell acute lymphoblastic leukemia (ALL).

Bezerra discusses why 91% of patients deemed ineligible for the ZUMA-3 trial (NCT02614066), and how the real-world population compares. Notably, the most common reason for ineligibility was low disease burden, with nearly 40% of patients having less than 5% bone marrow blasts, a minimum requirement for ZUMA-3. Despite these differences, the study demonstrates high effectiveness of brexu-cel in this real-world setting.

Further, he highlights the specific subgroups of patients who responded particularly well or poorly to brexu-cel in this research. These data suggest that brexu-cel may be broadly effective across various patient subgroups within the relapsed/refractory B-cell ALL population.

Transcription:

0:09 | A very interesting finding of our research was that 91% of the patients would not be or would potentially be ineligible to submit to clinical trials, showing a difference of the patient population of treating the trial in the real-world patient population. One of the most common reasons was a low disease burden and around 40% of our patients had less than 5% bone marrow blasts, that was the minimum requirements in the clinical trial. And despite this difference in the reward setting that showed that patients who had brexu-cel were highly effective.

0:41 | Another interesting finding of our data is that is the subgroup analysis that we performed by looking at patients that were in [complete response] or not, had MRD or not, had prior blinatumomab [Blincyto] or not, had the extramedullary disease or not, had a prior transplant or not, didn't see a significant difference in the effective outcomes, like [complete response rate], relapse-free survival, overall survival, [and more].